These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

623 related items for PubMed ID: 24508063

  • 1. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.
    Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D.
    Mol Oncol; 2014 May; 8(3):565-80. PubMed ID: 24508063
    [Abstract] [Full Text] [Related]

  • 2. Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation.
    Wang WD, Shang Y, Li Y, Chen SZ.
    Acta Pharmacol Sin; 2019 Sep; 40(9):1219-1227. PubMed ID: 31235819
    [Abstract] [Full Text] [Related]

  • 3. Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer.
    Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D.
    Oncotarget; 2015 Oct 06; 6(30):29947-62. PubMed ID: 26359358
    [Abstract] [Full Text] [Related]

  • 4. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition.
    Xiong H, Hong J, Du W, Lin YW, Ren LL, Wang YC, Su WY, Wang JL, Cui Y, Wang ZH, Fang JY.
    J Biol Chem; 2012 Feb 17; 287(8):5819-32. PubMed ID: 22205702
    [Abstract] [Full Text] [Related]

  • 5. Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner.
    Avtanski DB, Nagalingam A, Kuppusamy P, Bonner MY, Arbiser JL, Saxena NK, Sharma D.
    Oncotarget; 2015 Jun 30; 6(18):16396-410. PubMed ID: 26036628
    [Abstract] [Full Text] [Related]

  • 6. Honokiol Inhibits Constitutive and Inducible STAT3 Signaling via PU.1-Induced SHP1 Expression in Acute Myeloid Leukemia Cells.
    Bi L, Yu Z, Wu J, Yu K, Hong G, Lu Z, Gao S.
    Tohoku J Exp Med; 2015 Nov 30; 237(3):163-72. PubMed ID: 26466521
    [Abstract] [Full Text] [Related]

  • 7. Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP.
    Lv XQ, Qiao XR, Su L, Chen SZ.
    Acta Pharmacol Sin; 2016 Dec 30; 37(12):1574-1586. PubMed ID: 27593221
    [Abstract] [Full Text] [Related]

  • 8. Honokiol Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway.
    Pan J, Lee Y, Zhang Q, Xiong D, Wan TC, Wang Y, You M.
    Cancer Prev Res (Phila); 2017 Feb 30; 10(2):133-141. PubMed ID: 27849557
    [Abstract] [Full Text] [Related]

  • 9. Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression.
    Bakiri L, Macho-Maschler S, Custic I, Niemiec J, Guío-Carrión A, Hasenfuss SC, Eger A, Müller M, Beug H, Wagner EF.
    Cell Death Differ; 2015 Feb 30; 22(2):336-50. PubMed ID: 25301070
    [Abstract] [Full Text] [Related]

  • 10. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells.
    Yu JM, Sun W, Hua F, Xie J, Lin H, Zhou DD, Hu ZW.
    Cancer Lett; 2015 Sep 01; 365(2):190-200. PubMed ID: 26049022
    [Abstract] [Full Text] [Related]

  • 11. Honokiol: A polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-β/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo.
    Pulivendala G, Bale S, Godugu C.
    Toxicol Appl Pharmacol; 2020 Mar 15; 391():114913. PubMed ID: 32032644
    [Abstract] [Full Text] [Related]

  • 12. Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.
    Sengupta S, Nagalingam A, Muniraj N, Bonner MY, Mistriotis P, Afthinos A, Kuppusamy P, Lanoue D, Cho S, Korangath P, Shriver M, Begum A, Merino VF, Huang CY, Arbiser JL, Matsui W, Győrffy B, Konstantopoulos K, Sukumar S, Marignani PA, Saxena NK, Sharma D.
    Oncogene; 2017 Oct 12; 36(41):5709-5721. PubMed ID: 28581518
    [Abstract] [Full Text] [Related]

  • 13. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition.
    Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, Hu M, Yu M, Qian L, Guo N.
    Oncogene; 2013 Nov 07; 32(45):5272-82. PubMed ID: 23318420
    [Abstract] [Full Text] [Related]

  • 14. Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling.
    Li W, Wang Q, Su Q, Ma D, An C, Ma L, Liang H.
    Mol Cells; 2014 May 07; 37(5):383-8. PubMed ID: 24810210
    [Abstract] [Full Text] [Related]

  • 15. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
    Lee JY, Park MK, Park JH, Lee HJ, Shin DH, Kang Y, Lee CH, Kong G.
    Oncogene; 2014 Mar 06; 33(10):1325-35. PubMed ID: 23474752
    [Abstract] [Full Text] [Related]

  • 16. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
    Esparza-López J, Alvarado-Muñoz JF, Escobar-Arriaga E, Ulloa-Aguirre A, de Jesús Ibarra-Sánchez M.
    BMC Cancer; 2019 Jul 23; 19(1):728. PubMed ID: 31337349
    [Abstract] [Full Text] [Related]

  • 17. Src promotes EGF-induced epithelial-to-mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT.
    Zhao L, Li X, Song N, Li A, Hou K, Qu X, Che X, Liu Y.
    Cell Biol Int; 2018 Mar 23; 42(3):294-302. PubMed ID: 29052277
    [Abstract] [Full Text] [Related]

  • 18. HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer.
    Zhang W, Shi X, Peng Y, Wu M, Zhang P, Xie R, Wu Y, Yan Q, Liu S, Wang J.
    PLoS One; 2015 Mar 23; 10(6):e0129603. PubMed ID: 26057751
    [Abstract] [Full Text] [Related]

  • 19. An hTERT/ZEB1 complex directly regulates E-cadherin to promote epithelial-to-mesenchymal transition (EMT) in colorectal cancer.
    Qin Y, Tang B, Hu CJ, Xiao YF, Xie R, Yong X, Wu YY, Dong H, Yang SM.
    Oncotarget; 2016 Jan 05; 7(1):351-61. PubMed ID: 26540342
    [Abstract] [Full Text] [Related]

  • 20. CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer.
    Lorenzatti G, Huang W, Pal A, Cabanillas AM, Kleer CG.
    J Cell Sci; 2011 May 15; 124(Pt 10):1752-8. PubMed ID: 21525039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.